Occam’s Razor and Hickam’s Dictum: A Rare Case of Synchronous Solid and Hematological Malignancies and Transformed EGFR-Mutated NSCLC Ciara Conduit,

Slides:

Advertisements

Similar presentations

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab Monica Khunger, MD Journal of Thoracic.

Advertisements

Next Generation Sequencing Uncovers Potential Genetic Driver Mutations of Malignant Pulmonary Granular Cell Tumor Song Xu, Qingchun Zhao, Sen Wei, Yi.

Hironori Yoshida, MD, Young Hak Kim, MD Journal of Thoracic Oncology

Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD Journal of Thoracic Oncology

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

SC17.02 Lung Cancer in China: Challenges and Perspectives

Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation Alessandro Russo, MD, Tindara.

Response to Osimertinib in Choroidal Metastases from EGFRmt T790M–Positive Non– Small Cell Lung Adenocarcinoma Filippo Gustavo Dall’Olio, MD, Celeste.

Sclerosing Pneumocytoma with Lymph Node Metastasis

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

Erlotinib Response in an NSCLC Patient with a Novel Compound G719D+L861R Mutation in EGFR Eamon M. Berge, MD, Dara L. Aisner, MD, PhD, Robert C. Doebele,

David T. Cooke, MD, Dennis J. Zheng, Karen A. Peterson, NP, Royce F

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Jos A. Stigt, MD, PhD, Richard Vossenkaul, MD, Wouter H

MET-Mutated NSCLC with Major Response to Crizotinib

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab Monica Khunger, MD Journal of Thoracic.

KRAS Mutation Analysis Helps to Differentiate Between Pulmonary Metastasis from Colon Adenocarcinoma In Situ and Primary Lung Adenocarcinoma Taylor M.

Complete Response Achieved 1 Year after a Single Administration of Nivolumab in a Patient with Lung Adenocarcinoma with Negative Expression of PD-L1

Long-Lasting Response to Nivolumab and Immune-Related Adverse Events in a Nonsquamous Metastatic Non–Small Cell Lung Cancer Patient Biagio Ricciuti,

Hironori Yoshida, MD, Young Hak Kim, MD Journal of Thoracic Oncology

Cyclooxygenase-2 Expression in Non-Small Cell Lung Cancer Correlates With Hypertrophic Osteoarthropathy Ioannis Rotas, Giovanni Cito, Igor Letovanec,

Coexistence of the BRAF Mutation and EGFR Exon 20 Insertion in a Patient with Lung Adenocarcinoma Lih-Chyun Chang, MD, Kuan-Yu Chen, MD, PhD, Jin-Yuan.

Small Cell Transformation and T790M Mutation as Coresistance Mechanisms for First- line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor.

A Severe Photosensitivity Dermatitis Caused by Crizotinib

A Case of Invasive Mucinous Pulmonary Adenocarcinoma with a CD74-NRG1 Fusion Protein Targeted with Afatinib Parneet K. Cheema, MD, MBiotech, FRCPC Journal.

Daniel G. Stover, MD, Rosana Eisenberg, MD, David H. Johnson, MD

Histologic Transformation in NSCLC with PD-1 therapy

Cardiac Dysfunction Caused by Osimertinib

Effective Treatment with Icotinib in Primary Adenoid Cystic Carcinoma of the Lung with Liver Metastasis Zhengbo Song, MD, Wei Wu, MD, Yiping Zhang, MD

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

Erik Jakobsen, Maria Iachina, Karen Ege Olsen, Anders Green

Ritbune Prakobkit, MD, William Churk-Nam Auyeung, MD

Transformation to SCLC after Treatment with the ALK Inhibitor Alectinib Shiro Fujita, MD, PhD, Katsuhiro Masago, MD, PhD, Nobuyuki Katakami, MD, PhD,

Jamie A. Saxon, PhD, Lynette M. Sholl, MD, Pasi A. Jänne, MD, PhD

The role of positron emission tomography for non-small cell lung cancer Albert J. Chang, MD, PhD, Farrokh Dehdashti, MD, Jeffrey D. Bradley, MD Practical.

Primary Malignant Pericardial Mesothelioma Mimicking Pericardial Metastasis from Adenocarcinoma Masafumi Horie, MD, Satoshi Noguchi, MD, Wakae Tanaka,

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

Aya Fukuizumi, MD Journal of Thoracic Oncology

A Different Method in Diagnosis of Multiple Primary Lung Cancer

Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response

Arnaud Uguen, MD, PhD Journal of Thoracic Oncology

A Case of ALK-Rearranged Adenocarcinoma with Small Cell Carcinoma-Like Transformation and Resistance to Crizotinib Yoon Jin Cha, MD, PhD, Byoung Chul.

PET/CT Findings for Bone Marrow Carcinosis Because of Lung Adenocarcinoma Keisuke Watanabe, MD, Masaharu Shinkai, MD, PhD, Kenjiro Nagai, MD, Nobuhiro.

ED11.01 Systemic Therapy for Advanced Oncogene-Driven NSCLC

Small Cell Lung Cancer Transformation as a Mechanism of Resistance to PD-1 Therapy in KRAS-Mutant Lung Adenocarcinoma: A Report of Two Cases Wade T.

Elizabeth Cathcart-Rake, MD, Ariel Lopez-Chavez, MD, MS

Steve R. Siegal, MD, John G. Hunter, MD, James P. Dolan, MD, MCR

Positron Emission Tomography 18F-Fluorodeoxyglucose Uptake and Prognosis in Patients with Surgically Treated, Stage I Non-small Cell Lung Cancer: A Systematic.

Vamsidhar Velcheti, MD Journal of Thoracic Oncology

Combination Treatment Using an EGFR Tyrosine Kinase Inhibitor plus Platinum-Based Chemotherapy for a Patient with Transformed Small Cell Carcinoma and.

An Unmet Need in the WHO 2015 Biopsy Classification: Poorly Differentiated NSCCs with Positive Neuroendocrine Markers Jules L. Derks, MD Journal of.

Osimertinib for Epidermal Growth Factor Receptor Mutation–Positive Lung Adenocarcinoma That Transformed to T790M-Positive Squamous Cell Carcinoma Naoyuki.

EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer Allison Ackerman, MD, Michael A. Goldstein,

S768I Mutation in EGFR in Patients with Lung Cancer

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD,

Beware of the “Bronchocele,” Particularly in Patients with a History or Risk Factors for a Mucinous Carcinoma: A Response to the Article “Resection of.

Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non– Small Cell Lung Cancer Emily Castellanos, MD, Emily Feld, MD, Leora.

The Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Lung Cancer: Still Following the Right TRAIL? Emmet E. McGrath, MB, PhD Journal of Thoracic.

Pulmonary Atelectasis after Stereotactic Ablative Radiotherapy for a Central Lung Tumor Sashendra Senthi, MBChB, FRANZCR, Eric F Ullmann, MD, Suresh.

Pitfalls in Oncology: Osteoblastic Response Mimicking Bone Progression during Ceritinib Treatment in ALK-Rearranged NSCLC Francesco Gelsomino, MD, Valentina.

Marianna Koczywas, MD, Mihaela C. Cristea, MD

Highly Sensitive Detection of EGFR T790M Mutation in Pre-TKI Specimens of EGFR- Mutated NSCLC: In Cis, In Trans, or a Different Clone? Alvaro Leone, BSc.D

Impressive Response to Tyrosine Kinase Inhibitors in a Patient with Respiratory Failure for EGFR-Mutated Metastatic Lung Cancer Elena Bolzacchini, MD,

Metastatic Lung Cancer to the Pancreas

Successful AZD9291 Therapy Based on Circulating T790M

Tumor Lysis Syndrome in Limited-Stage Small-Cell Lung Cancer

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Regression of Paraneoplastic Rash after Lung Cancer Chemotherapy

Robert Comis, MD, The Passing of a “Lung Man”

Presentation transcript:

Occam’s Razor and Hickam’s Dictum: A Rare Case of Synchronous Solid and Hematological Malignancies and Transformed EGFR-Mutated NSCLC Ciara Conduit, M.B.B.S., Ashutosh Hardikar, M.B.B.S., Ritam Prasad, M.B.B.S., Louise Nott, M.B.B.S. Journal of Thoracic Oncology Volume 11, Issue 11, Pages e131-e133 (November 2016) DOI: 10.1016/j.jtho.2016.06.027 Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Fused transaxial positron emission tomography images demonstrating reduction in the size of the primary tumor. Journal of Thoracic Oncology 2016 11, e131-e133DOI: (10.1016/j.jtho.2016.06.027) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 Maximum-intensity projection positron emission tomography images showing new and persistent fludeoxyglucose F 28–avid skeletal uptake across a 15-month period. Journal of Thoracic Oncology 2016 11, e131-e133DOI: (10.1016/j.jtho.2016.06.027) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 3 Initial lung biopsy specimen (A) showing focal infiltration of adenocarcinoma. Bone biopsy specimen (B) demonstrating replacement of marrow space by atypical lymphoreticular proliferation that is CD20 positive (C). Subsequent lobectomy (D) demonstrating poorly differentiated adenocarcinoma adjacent to small cell carcinoma that is positive for synaptophysin (E) and CAM5.2 (F). Journal of Thoracic Oncology 2016 11, e131-e133DOI: (10.1016/j.jtho.2016.06.027) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions